AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodege...
November 21 2017 - 8:32AM
Lausanne, Switzerland, November 21, 2017
- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage
biopharmaceutical company with a broad pipeline focused on
neurodegenerative diseases, today announced that it will host a Key
Opinion Leader (KOL) luncheon meeting on the importance of Tau as a
target in Alzheimer's disease and other neurodegenerative diseases
on December 1, 2017 from 12.00pm - 1.45pm ET at the St. Regis
Hotel, 2 E. 55th Street in New York, NY.
The meeting will feature presentations by KOLs
Khalid Iqbal, PhD (New York State Institute for Basic Research in
Developmental Disabilities) and Michael Rafii, MD, PhD (UC San
Diego). They will discuss the mechanism and importance of Tau
in the pathology and treatment of Alzheimer's and other
neurodegenerative diseases, the role of diagnostics in Alzheimer's
and a review of research on Tau and Amyloid in people with Down
syndrome.
AC Immune's management team will provide an
overview of the Company's robust and diverse pipeline of nine
therapeutic and three diagnostic product candidates. The Company
has a clear strategy to invest and build value in each of the three
pillars of its business -- Alzheimer's disease, other significant
neurodegenerative diseases and neuro-orphan indications, and
diagnostics.
A Q&A session with the featured KOLs and the
management will follow the presentations.
This event is intended for institutional
investors, sell-side analysts, and pharmaceutical business
development professionals only. Please RSVP in advance if you plan
to attend, as space is limited.
A live webcast and replay of the event will be
available on the Investor Page of AC Immune's website.
KOL Biographies
Khalid Iqbal, PhDDr. Khalid Iqbal is
Professor and Chairman, Department of Neurochemistry at the New
York State Institute for Basic Research in Developmental
Disabilities, Staten Island, New York. He received his PhD in
Biochemistry in 1969 from the University of Edinburgh, Edinburgh,
U.K. Dr. Iqbal was the first to bulk-isolate neurofibrillary
tangles and decipher their protein composition from autopsied
brains of cases with Alzheimer's disease in 1974. These pioneering
studies led him to the discoveries of Tau protein as the major
protein subunit of the tangles and its abnormal
hyperphosphorylation in Alzheimer's disease in 1986. Dr. Iqbal has
received numerous awards, including the Potamkin Prize for
Alzheimer Disease Research from the American Academy of Neurology,
the Zenith Award from the Alzheimer's Association, U.S.A and
Honorary Doctor of Science degree from the City University of New
York College of Staten Island. In 2007, Alzheimer's Association,
USA, established a Khalid Iqbal Life Time Achievement Award for
Alzheimer's Disease Research, which is given out annually at the
International Conference on Alzheimer's Disease (AAIC) to a senior
established Alzheimer disease researcher. Dr. Iqbal has authored
over 400 scientific papers in prestigious American and
international scientific journals and edited seven books on
research advances in Alzheimer's disease and related
neurodegenerative disorders. He currently serves on editorial
boards of several journals and scientific advisory committees of
biotechnology companies.
Michael Rafii, MD, PhDDr. Michael Rafii,
MD, PhD, is a board-certified neurologist and Associate Professor
of Neuroscience and Founding Director of the Adult Down Syndrome
Clinic at UC San Diego. Dr. Rafii leads multiple research programs
studying the link between Alzheimer's disease and Down syndrome. He
completed a fellowship in dementia and cognitive disorders at UC
San Diego. He completed his neurology residency at the Johns
Hopkins Hospital, where he was chief resident. He received his
medical and doctorate degrees from Brown University School of
Medicine and conducted neurogenetics research at Harvard Medical
School. Dr. Rafii serves on the National Task Group on Intellectual
Disabilities and Dementia Practices of the American Academy of
Developmental Medicine and is co-editor of the textbook Common
Pathogenic Mechanisms between Down Syndrome and Alzheimer's
Disease: Steps toward Therapy. Dr. Rafii received the Star Award
from the Down Syndrome Association of San Diego for his efforts to
improve the lives of people with this condition. He is also
Clinical Director of the Alzheimer's Therapeutic Research Institute
(ATRI) at the Keck School of Medicine of USC.
About AC ImmuneAC Immune is a clinical
stage Swiss-based biopharmaceutical company focused on
neurodegenerative diseases with four product candidates in clinical
trials. The Company designs, discovers and develops therapeutic and
diagnostic products intended to prevent and modify diseases caused
by misfolding proteins. AC Immune's two proprietary technology
platforms create antibodies, small molecules and vaccines designed
to address a broad spectrum of neurodegenerative indications, such
as Alzheimer's disease (AD). The Company's pipeline features nine
therapeutic and three diagnostic product candidates. The most
advanced of these is crenezumab, an anti-Abeta antibody in Phase 3
clinical studies for AD that is being conducted by the
collaboration partner Genentech. Other collaborations include
Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health
Sciences, Piramal Imaging and Essex Bio-Technology.
Forward Looking StatementsThis
press release contains statements that constitute "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements are statements other than historical
fact and may include statements that address future operating,
financial or business performance or AC Immune's strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may," "might," "will," "should,"
"expects," "plans," "anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "outlook" or "continue," and
other comparable terminology. Forward-looking statements are based
on management's current expectations and beliefs and involve
significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially
from those contemplated by these statements. These risks and
uncertainties include those described under the captions "Item 3.
Key Information-Risk Factors" and "Item 5. Operating and Financial
Review and Prospects" in AC Immune's Annual Report on Form 20-F and
other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made,
and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except
as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
For further information, please
contact:
In EuropeEva SchierAC Immune Corporate Communications Phone:
+41 21 345 91 34E-mail: eva.schier@acimmune.com |
In the USLisa SherAC Immune Investor Relations Phone: +1 970
987 26 54E-mail: lisa.sher@acimmune.com |
Nick Miles /Toomas KullCabinet Privé de Conseils s.a.Phone: +41 22
552 46 46 E-mail: miles@cpc-pr.comkull@cpc-pr.com |
Ted AgneThe Communications Strategy Group Inc.Phone: +1 781 631
3117E-mail: edagne@comstratgroup.com |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/081f2383-2d4a-4e3c-923d-2f933d7522c4
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Mar 2024 to Apr 2024
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Apr 2023 to Apr 2024